hero image

Biogen Announces Publication of BIIB080 Phase 1b Data in Nature Medicine

April 28, 2023 Company Statements

Nature Medicine has published a manuscript detailing promising results from Biogen’s multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target engagement of Biogen’s BIIB080 (MAPT ASO), an investigational antisense oligonucleotide targeting tau mRNA in early-stage Alzheimer’s disease (AD).

These early stage data support our commitment to building on a deep expertise in Alzheimer’s Disease by advancing Biogen’s industry-leading Alzheimer's pipeline across therapeutic modalities and molecular targets.

A link to the manuscript is provided here: https://www.nature.com/articles/s41591-023-02326-3

Currently, the Phase 2 CELIA study of BIIB080 (NCT05399888) is in progress and recruiting participants in the United States.

In December 2019, Biogen exercised a license option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO).




September 29, 2023
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept.

September 26, 2023
Biogen Completes Acquisition of Reata Pharmaceuticals

Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition